Predicting immune checkpoint therapy efficacy of hepatocellular carcinoma
Lay Description
We propose to test whether H1 and H2 clustering can distinguish patients responsive or resistant to the combination therapy with immunotherapy in a prospective clinical study. |
Category
- Cancers and Other Neoplasms
- Immune System
- IRB Number
- 20220298HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- -
- Eligible Genders
- All
- Accepts Healthy Volunteers
Inclusion Criteria
1. Patients with HCC who are not candidates for curative or locoregional treatments .
2. Patients who are candidates to receive first-line immunotherapy-based regimens (i.e., atezolizumab/bevacizumab)
3. ECOG performance status 0-2
4. Patients who will have baseline biopsy for HCC and background liver biopsy per SOC
Exclusion Criteria
1. Prior systemic therapy for HCC
2. Any contraindication to immunotherapy
a) Prior transplant
b) Uncontrolled autoimmune diseases (i.e., autoimmune hepatitis)
3. Prior anti-PD-L1, anti-PD1, or anti-CTLA4 antibody (or another checkpoint inhibitor)
Study Design
Study Contact
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Principal Investigator
Sukeshi Arora